Patent ID: 8912157

Claim:
A method of upregulating a function of and/or the expression of a Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro comprising: contacting said cells or tissues with at least one single stranded antisense oligonucleotide 19 to 21 nucleotides in length wherein said at least one oligonucleotide has at least 90% sequence identity to a reverse complement of a polynucleotide comprising 19 to 21 consecutive nucleotides within the natural antisense polynucleotide selected from the group consisting of nucleotides 1 to 1235 of SEQ ID SEQ ID NO: 6, 1 to 17,964 of SEQ ID NO: 7, 1 to 1 to 50,003 of SEQ ID SEQ ID NO: 8, 1 to 486 of SEQ ID NO: 9, 1 to 494 of SEQ ID NO: 10, 1 to 1992 of SEQ ID NO: 11, or 1 to 1767 of SEQ ID NO: 12 and wherein said antisense oligonucleotide specifically targets said natural antisense polynucleotide; thereby upregulating a function of and/or the expression of the Pancreatic Developmental gene polynucleotide in patient cells or tissues in vivo or in vitro.